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OVARIAN METASTASES IN COLORECTAL CANCER AND PSEUDOMYXOMA 
PERITONEI WITH PERITONEAL METASTASES. 
 
Halle T¹², Haarklou J¹², Solbakken A¹, Larsen SG¹².  
 
Objective: The aim of this study was to evaluate the incidence, survival data 
and prognostic factors in a national treatment centre for CRS and HIPEC in 
Norway when ovarian metastases are found similarly with peritoneal 
metastases.  
 
Methods: Between 1993 and 2012, 152 consecutive women with 
Pseudomyxoma peritonei (PMP) and Peritoneal carcinomatosis (PCA) from 
colorectal cancer were treated for peritoneal disease. The patiens were 
treated radically with maximal cytoreductive surgery (CRS), followed by early 
postoperative intraperitoneal chemotherapy (EPIC) between 1993 and 2002, 
and with hyperthermic intraperitoneal chemotherapy (HIPEC) from 2003. 
Data regarding the patiens were prospectively registered into the institutional 
peritoneal surface malignancy database.  
 
Results: 152 patiens were included in the study group. 42 of 65 patiens 
treated for PCA (64,6%) had metastases to one or both ovaries at the time of 
surgery and HIPEC. The tumor grew infiltrating in all PCA patients. In the 
PMP group, 69 of 87 patients had ovarian metastases (79,3%) but fewer of 
these were infiltrating tumors (20,6%).  
The 5-year survival rates for all radical resections were 38.3% in PCA and 
85.8% in PMP. After complete surgical resection of PCA and preoperative 
HIPEC the 5-year survival rate for women with confirmed ovarian metastases 
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were 30.6% and for those without ovarian metastases 60.6% (p=0.049). The 
median survival time was less, 40 months in ovarian metastases whereas the 
median time was not reach in the group without (Figure 1). When we look at 
the progression free survival data in PCA we find the same with median 
survival times of 13 versus 28 months. 
When the patients with PCA had ovarian metastases, the tumour burden 
measured by the PCI value was higher (12.6 versus 6.8) and operation time 
longer (430 minutes versus 334 minutes). However, there was no difference 
in days of hospital stay or in values for CEA.  
There is a strong association between histopathological differentiation and 
invasiveness in patients with PMP with more infiltrating growth in the 
subgroup with peritoneal mucinous carcinomatosis 
 
Conclusion: Ovarial metastases are assosiated with advanced disease and poor 
survival rate. The high percentage of ovarian metastases both in PCA and PMP lead 
to the conclusion that bilateral oofrectomy should be performed during the CRS when 
peritoneal metastases and ovarian masses can represent spread from a colorectal 
primary tumour. Often the ovarian metastasis also is combined with peritoneal 
metastases. It is therefore important to evaluate the CEA, do a coloscopy and refer 
the patient to evaluation for CRS and HIPEC if colorectal origin is likely. This 
treatment can offer the patient best chances for cure are evident, regardless of age.  
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INTRODUCTION 
Approximately 30% of ovarian neoplasms are metastatic, and nearly half of 
them originate from the gastrointestinal tract1;2. A new pelvic mass in a 
woman with history of colorectal cancer is more likely metastatic (57%) than 
a benign (27%) or malignant ovarian tumour (16%)3. In a review of ovarian 
neoplasms in colorectal cancer the incidence of ovarian metastasis 
discovered at surgery or during follow-up was 0.8% - 7.4% and even higher 
5%-9.7% in post-mortem studies4.  
 
Pseudomyxoma peritonei (PMP) of appendiceal origin are often discovered in 
advanced stages of disease where also the ovaries are affected. In cases 
with voluminous ovarian masses, the condition often is confused with an 
ovarian primary even though cancer markers could point to a colorectal 
origin.  
 
Regarding colonic cancer, a prospective study from our institution5 has 
demonstrated peritoneal metastases in 10% of women. Peritoneal 
carcinomatosis is usually demonstrated late in disease progression because 
symptoms occur at an advanced stage of disease. Ovarian metastasis and 
peritoneal metastasis can occur concurrently but the incidence is unknown. 
The exact pathogenesis of colorectal cancer ovarian metastases in unknown 
and both transcoelomic spread, hematogenous spread, lymphatic spread and 
direct extension have been discussed as possible mechanisms4. A single 
centre report from the Netherlands showed 65% ovarian metastases in 
colorectal cancer (CRC) with peritoneal metastases5;6. Performing 
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prophylactic ooforectomy during primary treatment of colorectal cancer has 
therefore been a subject of debate, and simultaneous prophylactic removal 
during cytoreductive surgery for peritoneal carcinomatosis recommended 
because of high, particularly in post-menopausal women. 
 
Treatment has moved from palliation to aggressive treatment, and 
cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy 
(HIPEC) has become important in treatment of peritoneal metastasis from 
colorectal cancer7;8 with superior results and increase in the 5-year overall 
survival rate from zero to more than 40% in selected cases9;10.  
 
The aim of this study was to evaluate the incidence, survival data and 
prognostic factors in a national treatment centre for CRS and HIPEC in 
Norway when ovarian metastases are found concurrent with peritoneal 
metastases.  
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MATERIALS AND METHODS  
The Norwegian Radium Hospital is the national treatment centre in Norway 
for cytoreductive surgery (CRS) and perioperative intraperitoneal 
chemotherapy (PIC); handling both pseudomyxoma peritonei (PMP) and 
peritoneal metastases (PCA) from colorectal cancer.   
 
All women treated for PMP and PCA in the period from September 1993 to 
July 2012 were included in our institutional database MEDinsight approved 
by the Ethics Committee at the University of Oslo, 103 with PMP and 103 
with PCA (www.medinfo.net/imi/projects/medinsight). In seven of the PCA 
patients the following operation could not confirm peritoneal disease and they 
were excluded from the study. The number of women with PMP has been 
stable during the period whereas an increasing number of patients with PCA 
have been treated after 2004. 10 patients in each group only underwent an 
explorative procedure due to extensive tumour burden whereas 5 with PMP 
and 19 with PCA underwent a palliative operation. As the study focuses on 
the ovarian disease, 2 with previous ooforectomy for other reasons and 1 
with no available information regarding the ovaries were excluded (Table 1). 
The remaining 152 patients with PMP (n=87) and PCA (n=65), hereafter 
referred to as the study group, were treated radically with maximal 
cytoreductive surgery (CRS) and in most cases also perioperative 
intraperitoneal chemotherapy (PIC) (except 2 with PMP and 2 with PCA) for 
elimination of microscopic residual disease. Between 1994 and 2002, PIC 
was administered as early postoperative intraperitoneal chemotherapy (EPIC, 
n=33 with PMP, n=0 with PCA), and from 2003 as hyperthermic 
intraperitoneal chemotherapy in both groups. The median age was 56 years 
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(24-74) in PMP and 57 years (30-74) in PCA. Data regarding the patients, 
disease and treatment were partly prospectively registered into the 
institutional peritoneal surface malignancy database, partly retrospectively 
obtained from the patient records. Preoperative work-up was based on 
operative reports from referring hospital along with CT scans of chest, 
abdomen and pelvis. All patients were discussed in our multidisciplinary team 
meeting consisting of dedicated radiologists, oncologists and colorectal 
surgeons.  
 
 
Definitions 
Tumour distribution on the peritoneal surface found during CRS was classified 
according to peritoneal cancer index (PCI); retrospectively estimated from operative 
reports and CT scans before 2003 and prospectively registered thereafter. Thirteen 
peritoneal regions were given a score from 0 to 3 based on tumour size: 0, no 
macroscopic tumour; 1, tumour < 0.5 cm; 2, tumour between 0.5 cm and 5 cm and 3, 
tumour > 5 cm or confluent tumours11. After being assigned a PCI score of 0 to 39, 
the patients were categorized into three groups according to PCI intervals: PCI ≤ 10, 
PCI 11-20 and PCI ≥ 21. Patients operated in two séances were given the largest 
PCI score. 
  
Residual tumour after CRS was classified using the Completeness of Cytoreduction 
(CC) score where CC-0 means no residual tumour; CC-1 residual tumour < 0.25 cm; 
CC-2 residual tumour between 0.25 cm-2.5 cm and CC-3 larger residual tumour11. 
Only CC-0 or CC-1 was defined as a curative resection. 
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Ovarian metastasis was defined as the presence of malignant cells in at least one of 
the ovaries either before or during CRS and PIC. Disease free survival is calculated 
as the time from CRS-PIC until time of recurrence. 
 
Treatment 
CRS was conducted with surgical resection of all tumour bearing peritoneum and 
necessary organ resections to remove all macroscopic tumour deposits. This 
included a bilateral ooforectomy in most patients. EPIC (1993-2002) was given as 
Mitomycin C (MMC) 10 mg/m2 on day 1 and 5-fluoruracil (5-FU) 650 mg/m2 on days 
2-5. The drugs were diluted in 1000 ml dextrose and were contained intraperitoneally 
for 23 hours and followed by instillation of the next dose. For administration of 
HIPEC, the open Coliseum-technique was used from 2003 to 2008 when a semi-
open technique was introduced12;13. 
The perfusion system is previously described14. The drug used for HIPEC was MMC 
35 mg/m2 (maximum dose of 70 mg), divided in three fractions; 50% at 0 min, 25% at 
30 min and 25% at 60 min, and perfused for 90 min, in most cases directly following 
the CRS. The temperature was mean 41.0ºC. 
 
Histopathological evaluation 
All tissue samples regarding pseudomyxomas were classified into disseminated 
peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA) 
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and an intermediate group (PMCA-I)15. Peritoneal carcinomatosis was classified in 3 
grades; low, median and high differentiation. 
 
Follow-up 
The PMP patients attended the outpatient clinic for up to ten years, the first five years 
every six months and thereafter in most cases once a year. Follow-up included 
clinical examination, CT scans of chest, abdomen and pelvis and serum analyses of 
tumour markers (CEA, CA 19-9, CA 125). Local recurrence was defined as detection 
of tumour in the peritoneal cavity by CT scan. PCA patients were followed either in 
our outpatient clinic or by referring hospitals. Follow-up analysis was terminated on 
July 31th 2013. Date of death was obtained from the national health register. 
 
Statistical analysis 
Association between clinico-pathological data and extent of surgery in Table 
2 were analyzed using the Chi-Square test (Pearson’s and linear association 
as appropriate). Mann-Whitney test were used to test for differences between 
independent groups of quantitative variables. Curves of overall survival (OS) 
and disease-free survival (DFS) were calculated from the date of CRS and 
PIC with the Kaplan-Meier product-limit method, for OS until date of death 
and for DFS until date of first local or distant recurrence, or death. Uneventful 
postoperative courses were censored on July 31st, 2013 and on date of last 
follow-up (DFS). Differences between groups were analyzed using the log 
rank test. Survival is calculated from the date of cancer surgery in our 
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department. A two-sided p value of 0.05 or less was considered statistically 
significant. All calculations were performed using the Statistical Package for 
the Social Sciences® program, version 18.0 (SPSS GmBH, Chicago, Illinois, 
USA). 
 
There is no funding source. 
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RESULTS 
Ovarian Metastases 
42 of 65 patients treated for PCA (64.6%) had metastases to one or both 
ovaries at the time of surgery and HIPEC. The ovarian tumour showed 
infiltrating growth in all PCA patients. When the patients with PCA had 
ovarian metastases, the tumour burden measured by the PCI value was 
higher (12.6 versus 6.8) and operation time longer (430 minutes versus 334 
minutes). However, there was no difference in days of hospital stay or in 
values for CEA. More descriptive data of the patients in the study group are 
specified in Table 2.  
In the PMP group 69 of 87 patients had ovarian metastases (79.3%) but fewer had 
infiltrating tumours than in patients with PCA (20.6%). PCI was higher (20.1 versus 
8.7) when ovarian disease was present in PMP and median values for CEA was 
higher (58.9 versus 9.6) There is a strong association between histopathological 
differentiation and invasiveness in patients with PMP with the subgroup with 
peritoneal mucinous carcinomatosis (PMCA) showing more infiltrating growth 
(p<0.001) (Table 2).  
 
Survival 
The 5-year survival rates for all radical resections were 38.3% in PCA and 
85.8%. The median survival times were 46 months in PCA whereas the 
median times were not reached in PMP. After complete surgical resection of 
PCA and perioperative HIPEC the 5-year survival rate for women with 
confirmed ovarian metastases were 30.6% and for those without ovarian 
metastases 60.6% (p=0.049). The median survival time was less (40 months) 
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in ovarian metastases whereas the median survival time was not reach in the 
group without metastases (Figure 1). When we look at the progression free 
survival data in PCA we find the same with median survival times of 13 
versus 28 months (Figure 2). 
 
 
 
 13 
DISCUSSION 
A previous study has documented an incidence of ovarian metastases of 
65% in patients with peritoneal metastases from colorectal cancer6. In the 
present study from the only treatment centre for HIPEC in Norway (national 
cohort) we found 60% of women treated for peritoneal metastases after 
colorectal cancer also to have ovarian metastases and an even higher rate of 
80% in pseudomyxoma peritonei. However, all patients in our study have 
peritoneal involvement, even though the PCI values are higher among 
patients with ovarian metastases.  
 
Peritoneal carcinomatosis together with ovarian metastases is best treated by 
maximal cytoreductive surgery and HIPEC. Patients with colorectal cancer 
that present with ovarian metastases at primary surgery without other 
macroscopically peritoneal metastases are at risk of developing peritoneal 
carcinomatosis. Elias et al. therefore recommend second-look and CRS-
HIPEC to patients with colorectal ovarian metastases16.  
 
Colorectal cancer that is metastatic to the ovaries poses a difficult problem 
for the clinicians. Treatment outside a colorectal cancer unit can lead to 
inferior treatment without resection of all peritoneal disease and possibly also 
without the additional benefit of intraoperative chemotherapy. Surgery in two 
séances has, in addition, been demonstrated inferior regarding survival17. 
Since ovarian masses can represent spread from a colorectal primary 
tumour, and often is combined with peritoneal metastases, it is important to 
evaluate the carcino-embryonal index (CEA), do a coloscopy and refer the 
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patient to evaluation for CRS and HIPEC if colorectal origin is likely. This 
treatment can offer the patient best chances for cure. 
 
After dedicated resection for colorectal carcinomatosis and HIPEC this study 
offers good results both in women with confirmed ovarian metastases and 
those with disease-free ovaries with estimated 5-year survival rates in one-
third and two-thirds of the patients, in contrast to no long term survival after 
surgery and systemic chemotherapy. However, the progression-free survival 
in both groups is lower. 
 
When peritoneal metastases are present in colorectal cancer and ovarian 
involvement was not obvious during HIPEC, one study demonstrated 40% 
microscopically disease in colorectal carcinomatosis, 24% in PMCA and 41% 
in DPAM6. Several studies found that, depending on age, prophylactic 
ooforectomy also will eliminate chances for an ovarian primary.  Therefore we 
recommend bilateral ooforectomy in women with peritoneal metastases and 
colorectal cancer, irrespective of age. 
  
 15 
CONCLUSION 
Due to high incidence of ovarian metastases both in colorectal cancer with 
peritoneal metastases and in pseudomyxoma peritonei, a number of patients 
with microscopically ovarian disease and inferior prognosis in the patients, 
bilateral ooforectomy should be performed during the CRS when peritoneal 
metastases are evident, regardless of age. The patients should be treated in 
a centre that offers HIPEC16. 
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Table	  1:	  Flow	  chart	  of	  patients	  with	  peritoneal	  metastasis	  and	  concurrent	  ovarian	  metastasis	  
206	  operated	  
	  
7	  no	  sign	  of	  carcinomatosis	  at	  surgery	  
199	  
20	  explorative	  surgery	  
	  
24	  palliative	  surgery	  
155	  
2	  earlier	  ooforectomy	  
1	  unknown	  status	  both	  ovaries	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  152	  	  	  	  	  	  	  	  	  87	  PMP	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  65	  PCA	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Table 2: Descriptive data in women with peritoneal carcinomatosis from colorectal 
cancer (n=65) and pseudomyxoma peritonei (n=87) stratified on simultaneous 
ovarian metastases or not 
 
 
  PCA (n=65) PMP (n=87) 
  met + (42) Met – (23) p met + (69) Met – (18) p 
age  55.64 
(52.29-
59.00) 
53.65 
(49.28-
58.02) 
ns 54.1(51.2-
57.1) 
56.5(51.0-
62.0) 
ns 
PSS 0 6 1 ns 9 6 0.02 
 1 8 8  10 6  
 2 22 12  47 4  
 3 2 1  3 2  
PCI 4 delt 0-10 19 20 0.005 16 14 <0.01 
 11-20 16 3  25 3  
 21-30 6 0  23 1  
 >30 1 0  5 0  
CC 0 32 20 Analyse01 53 17 Analyse01 
 1 2 0  10 0  
Infiltrating 
growth 
ovarries 
 42 0 0.000 18 0 0.000 
CEA  108.81 
(15.87-
201.74) 
85.21 (0-
248.80) 
ns 58.94 
(28.71-
89.18) 
9.63 (1.18-
18.08) 
 
Hospital stay  12.97 
(10.00-
15.95) 
10.45 
(8.26-
12.65) 
ns 19.88 
(15.14-
24.61) 
13.33 (9.79-
16.87) 
ns 
PCI  12.57 
(10.46-
14.68) 
6.81 (4.66-
8.96) 
 20.13 
(17.16-
23.20) 
8.73 (2.77-
14.68) 
 
PCImax  13.2 (11.1-
15.3) 
6.9 (4.9-
8.9) 
 20.4 (17.5-
23.3) 
8.73 (2.8-
14.7) 
 
Operation time 
(min) 
 430 (379-
481) 
334 (301-
368) 
 359 (310-
408) 
267 (182-
353) 
ns 
PIC none 1 1  1 1 ns 
 EPIC - -  27 6  
 HIPEC 41 22  41 11  
histology high    - - - 
 median    - - - 
 low    - - - 
 DPAM - - - 46 13 ns 
 PMCA-
IM 
- - - 10 1  
 PMCA - - - 13 4  
Total survival mnt 40 Not reached  Not reached Not reached ns 
 % 5 
year 
30.6 60.6  85.4 83.3  
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Figure 1: Survival in patients with peritoneal metastases from colorevtal cancer 
stratified on women with confirmed ovarian metastases and those with disease-free 
ovaries 
 
 
p=0.049 
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Figure 2: Progression-free survival in patients with peritoneal metastases from 
colorevtal cancer stratified on women with confirmed ovarian metastases and those 
with disease-free ovaries 
 
 
 
p=0.03 
 
 
